Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts

Vincent G. Valentine, Robert C. Robbins, John H. Wehner, Hiren R. Patel, Gerald J. Berry, James Theodore

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Persistent or recurrent acute allograft rejection (AR) refractory to high- dose steroid therapy can adversely affect long-term outcomes of heart-lung (HLT), bilateral-lung (BLT), and single-lung (SLT) transplantations. The use of total lymphoid irradiation (TLI) for the management of refractory acute AR in six transplant recipients (two men, four women; mean age, 29.8±3.8 years) is detailed. There are two HLT (primary pulmonary hypertension [PPH], cystic fibrosis [CF]), 1 BLT (pulmonary hypertension postventricular septal defect repair), and 3 SLT (sarcoid, PPH, congenital heart disease with atrial septal defect) recipients. Refractory AR is defined as persistent rejection unresponsive to high-dose steroid therapy in all cases. The BLT and SLT recipients had at least two moderate and one mild AR events per patient. The HLT recipients had at least two moderate acute heart and one severe and one mild asynchronous acute lung rejection events per patient. A total of 800 cGy of total lymphoid irradiation (TLI) was administered over a 5-week period. Mild and transient leukopenia was the only observed side effect. The patient with PPH received TLI 313 days after HLT for recurrent AR at another institution and died of ARDS 4 weeks after completing TLI. The patient with CF received TLI 707 days after HLT and died 457 days after TLI of severe obliterative bronchiolitis (OB) with multiorgan failure. The patient with BLT received TLI 176 days after transplant and died 372 days after TLI of respiratory failure related to severe rejection. One patient with SLT received TLI 78 days after transplant and died 679 days after TLI of severe acute AR. The two remaining patients with SLTs have been free from acute AR for more than 4 years. The patient with sarcoidosis received TLI 37 days after SLT following a clinical rejection event and two severe acute AR events. He is alive with normal lung function 5 years later. The patient with PPH received TLI 108 days after SLT following three moderate acute AR events and is alive with stable OB 4 years later. These limited preliminary results suggest that TLI has merit for the treatment of intractable acute AR following HLT and lung transplantation.

Original languageEnglish (US)
Pages (from-to)1184-1189
Number of pages6
JournalChest
Volume109
Issue number5
StatePublished - 1996
Externally publishedYes

Fingerprint

Lymphatic Irradiation
Allografts
Lung
Bronchiolitis
Lung Transplantation
Cystic Fibrosis
Steroids
Transplants
Atrial Heart Septal Defects
Leukopenia
Sarcoidosis
Pulmonary Hypertension

Keywords

  • acute lung rejection
  • immunosuppression
  • lung transplantation
  • radiotherapy
  • total lymphoid irradiation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Valentine, V. G., Robbins, R. C., Wehner, J. H., Patel, H. R., Berry, G. J., & Theodore, J. (1996). Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest, 109(5), 1184-1189.

Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. / Valentine, Vincent G.; Robbins, Robert C.; Wehner, John H.; Patel, Hiren R.; Berry, Gerald J.; Theodore, James.

In: Chest, Vol. 109, No. 5, 1996, p. 1184-1189.

Research output: Contribution to journalArticle

Valentine, VG, Robbins, RC, Wehner, JH, Patel, HR, Berry, GJ & Theodore, J 1996, 'Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts', Chest, vol. 109, no. 5, pp. 1184-1189.
Valentine VG, Robbins RC, Wehner JH, Patel HR, Berry GJ, Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest. 1996;109(5):1184-1189.
Valentine, Vincent G. ; Robbins, Robert C. ; Wehner, John H. ; Patel, Hiren R. ; Berry, Gerald J. ; Theodore, James. / Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. In: Chest. 1996 ; Vol. 109, No. 5. pp. 1184-1189.
@article{ae83a8a936a5413f9e12d23015373b9c,
title = "Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts",
abstract = "Persistent or recurrent acute allograft rejection (AR) refractory to high- dose steroid therapy can adversely affect long-term outcomes of heart-lung (HLT), bilateral-lung (BLT), and single-lung (SLT) transplantations. The use of total lymphoid irradiation (TLI) for the management of refractory acute AR in six transplant recipients (two men, four women; mean age, 29.8±3.8 years) is detailed. There are two HLT (primary pulmonary hypertension [PPH], cystic fibrosis [CF]), 1 BLT (pulmonary hypertension postventricular septal defect repair), and 3 SLT (sarcoid, PPH, congenital heart disease with atrial septal defect) recipients. Refractory AR is defined as persistent rejection unresponsive to high-dose steroid therapy in all cases. The BLT and SLT recipients had at least two moderate and one mild AR events per patient. The HLT recipients had at least two moderate acute heart and one severe and one mild asynchronous acute lung rejection events per patient. A total of 800 cGy of total lymphoid irradiation (TLI) was administered over a 5-week period. Mild and transient leukopenia was the only observed side effect. The patient with PPH received TLI 313 days after HLT for recurrent AR at another institution and died of ARDS 4 weeks after completing TLI. The patient with CF received TLI 707 days after HLT and died 457 days after TLI of severe obliterative bronchiolitis (OB) with multiorgan failure. The patient with BLT received TLI 176 days after transplant and died 372 days after TLI of respiratory failure related to severe rejection. One patient with SLT received TLI 78 days after transplant and died 679 days after TLI of severe acute AR. The two remaining patients with SLTs have been free from acute AR for more than 4 years. The patient with sarcoidosis received TLI 37 days after SLT following a clinical rejection event and two severe acute AR events. He is alive with normal lung function 5 years later. The patient with PPH received TLI 108 days after SLT following three moderate acute AR events and is alive with stable OB 4 years later. These limited preliminary results suggest that TLI has merit for the treatment of intractable acute AR following HLT and lung transplantation.",
keywords = "acute lung rejection, immunosuppression, lung transplantation, radiotherapy, total lymphoid irradiation",
author = "Valentine, {Vincent G.} and Robbins, {Robert C.} and Wehner, {John H.} and Patel, {Hiren R.} and Berry, {Gerald J.} and James Theodore",
year = "1996",
language = "English (US)",
volume = "109",
pages = "1184--1189",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts

AU - Valentine, Vincent G.

AU - Robbins, Robert C.

AU - Wehner, John H.

AU - Patel, Hiren R.

AU - Berry, Gerald J.

AU - Theodore, James

PY - 1996

Y1 - 1996

N2 - Persistent or recurrent acute allograft rejection (AR) refractory to high- dose steroid therapy can adversely affect long-term outcomes of heart-lung (HLT), bilateral-lung (BLT), and single-lung (SLT) transplantations. The use of total lymphoid irradiation (TLI) for the management of refractory acute AR in six transplant recipients (two men, four women; mean age, 29.8±3.8 years) is detailed. There are two HLT (primary pulmonary hypertension [PPH], cystic fibrosis [CF]), 1 BLT (pulmonary hypertension postventricular septal defect repair), and 3 SLT (sarcoid, PPH, congenital heart disease with atrial septal defect) recipients. Refractory AR is defined as persistent rejection unresponsive to high-dose steroid therapy in all cases. The BLT and SLT recipients had at least two moderate and one mild AR events per patient. The HLT recipients had at least two moderate acute heart and one severe and one mild asynchronous acute lung rejection events per patient. A total of 800 cGy of total lymphoid irradiation (TLI) was administered over a 5-week period. Mild and transient leukopenia was the only observed side effect. The patient with PPH received TLI 313 days after HLT for recurrent AR at another institution and died of ARDS 4 weeks after completing TLI. The patient with CF received TLI 707 days after HLT and died 457 days after TLI of severe obliterative bronchiolitis (OB) with multiorgan failure. The patient with BLT received TLI 176 days after transplant and died 372 days after TLI of respiratory failure related to severe rejection. One patient with SLT received TLI 78 days after transplant and died 679 days after TLI of severe acute AR. The two remaining patients with SLTs have been free from acute AR for more than 4 years. The patient with sarcoidosis received TLI 37 days after SLT following a clinical rejection event and two severe acute AR events. He is alive with normal lung function 5 years later. The patient with PPH received TLI 108 days after SLT following three moderate acute AR events and is alive with stable OB 4 years later. These limited preliminary results suggest that TLI has merit for the treatment of intractable acute AR following HLT and lung transplantation.

AB - Persistent or recurrent acute allograft rejection (AR) refractory to high- dose steroid therapy can adversely affect long-term outcomes of heart-lung (HLT), bilateral-lung (BLT), and single-lung (SLT) transplantations. The use of total lymphoid irradiation (TLI) for the management of refractory acute AR in six transplant recipients (two men, four women; mean age, 29.8±3.8 years) is detailed. There are two HLT (primary pulmonary hypertension [PPH], cystic fibrosis [CF]), 1 BLT (pulmonary hypertension postventricular septal defect repair), and 3 SLT (sarcoid, PPH, congenital heart disease with atrial septal defect) recipients. Refractory AR is defined as persistent rejection unresponsive to high-dose steroid therapy in all cases. The BLT and SLT recipients had at least two moderate and one mild AR events per patient. The HLT recipients had at least two moderate acute heart and one severe and one mild asynchronous acute lung rejection events per patient. A total of 800 cGy of total lymphoid irradiation (TLI) was administered over a 5-week period. Mild and transient leukopenia was the only observed side effect. The patient with PPH received TLI 313 days after HLT for recurrent AR at another institution and died of ARDS 4 weeks after completing TLI. The patient with CF received TLI 707 days after HLT and died 457 days after TLI of severe obliterative bronchiolitis (OB) with multiorgan failure. The patient with BLT received TLI 176 days after transplant and died 372 days after TLI of respiratory failure related to severe rejection. One patient with SLT received TLI 78 days after transplant and died 679 days after TLI of severe acute AR. The two remaining patients with SLTs have been free from acute AR for more than 4 years. The patient with sarcoidosis received TLI 37 days after SLT following a clinical rejection event and two severe acute AR events. He is alive with normal lung function 5 years later. The patient with PPH received TLI 108 days after SLT following three moderate acute AR events and is alive with stable OB 4 years later. These limited preliminary results suggest that TLI has merit for the treatment of intractable acute AR following HLT and lung transplantation.

KW - acute lung rejection

KW - immunosuppression

KW - lung transplantation

KW - radiotherapy

KW - total lymphoid irradiation

UR - http://www.scopus.com/inward/record.url?scp=0029865198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029865198&partnerID=8YFLogxK

M3 - Article

C2 - 8625664

AN - SCOPUS:0029865198

VL - 109

SP - 1184

EP - 1189

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -